We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Alliance Pharma Plc | LSE:APH | London | Ordinary Share | GB0031030819 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.60 | -1.78% | 33.10 | 32.95 | 33.85 | 33.95 | 32.95 | 33.95 | 1,864,058 | 16:35:13 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 167.42M | 936k | 0.0017 | 195.88 | 179.87M |
| Date | Subject | Author | Discuss |
|---|---|---|---|
| 08/4/2024 10:52 | 20-22p is the level here. | the imperialist | |
| 08/4/2024 10:19 | City boys? Are you living in the 1980s? | buoycat | |
| 08/4/2024 09:02 | City boys are buying | blackhorse23 | |
| 08/4/2024 07:11 | https://www.londonst | blackhorse23 | |
| 07/4/2024 10:11 | Finals Tuesday. Not holding my breath. | wad collector | |
| 05/4/2024 18:52 | So you can keep trading it ha ha, you must think people are stupid Top up again? Lolz | tomzimerman | |
| 05/4/2024 14:42 | Keep buying the dip | blackhorse23 | |
| 05/4/2024 10:15 | Let's hope the markets don't expect a 30-40% uplift in share price like you told poor Jerry last week Ouch | tomzimerman | |
| 05/4/2024 09:58 | The group's auditor has determined that the volume of work required to complete the audit has exceeded its original expectations, necessitating a short delay in the reporting timetable," the statement said.Nevertheless, the company assured that details provided in its latest trading update in January "remain accurate".Alliance has already reported revenues of £182.7m for 2023, up 6% on the previous year, while underlying profits were said to be in line with market expectations. | blackhorse23 | |
| 05/4/2024 09:43 | Spamming everyone you can today Lloyds Bank (LLOY) 'On Topic only' - Thread - Post 28347 LLOY Lloyds Banking Group Plc Blackhorse23 05 Apr 2024 09:30https://www.lon | tomzimerman | |
| 05/4/2024 09:22 | Buying opportunity at this dip | blackhorse23 | |
| 05/4/2024 09:08 | Is that the catalyst that takes this into the 20s? | the imperialist | |
| 05/4/2024 08:59 | https://www.londonst | blackhorse23 | |
| 05/4/2024 08:59 | Alliance confirms that the details provided in the full year trading update on 29 January 2024 remain accurate. | blackhorse23 | |
| 05/4/2024 08:53 | Financial summaryThe Group delivered record see-through1 revenues in the Period of £182.7m (FY22: £172.0m), up 6% versus the prior period and up 7% at constant exchange rates ("CER"). Excluding sales from ScarAway and the US rights to Kelo-Cote in Q1 23, both acquired in March 2022 (the "US Acquisition"), like-for-like see-through revenues increased 6% CER. Continued strong consumer demand, particularly in China, drove significant recovery in Kelo-Cote franchise revenues in H2, leading to FY23 revenues of £63.2m, up 29% CER (FY22: £50.0m). Nizoral revenues increased 3% CER to £21.7m (FY22: £21.8m) whilst Amberen revenues declined 6% CER on an underlying basis (excluding the leading discount store account that was lost in 2022) and decreased 25% CER to £11.2m (FY22: £14.9m) on a reported basis. With Other Consumer brands up 5% CER to £40.3m (FY22: £38.4m), total see-through Consumer Healthcare revenues increased 11% CER to £136.4m. Prescription Medicine revenues were stable at £46.3m (FY22: £46.8m), reflecting a strong recovery in H2 as expected, as previously out of stock products became available. Underlying profit for the Period is anticipated to be in-line with market expectations. Cash and debtFree cash flow in the Period rose 34% to £21.1m (FY22: £15.8m) and net debt reduction continued, falling to £92.4m at 31 December 2023 (31 December 2022: £102.0m). Group leverage2 (as at 31 December 2023) is expected to be significantly below that at 30 June 2023 (2.7x), and in-line with previous guidance. | blackhorse23 | |
| 05/4/2024 08:52 | Has not changed the guidelines of the results published on 29th jan which is showing business is booming | blackhorse23 | |
| 05/4/2024 08:51 | No volume will go up today | blackhorse23 | |
| 05/4/2024 07:32 | Buy on the coming dip. DYOR | queenbreguet | |
| 05/4/2024 07:14 | Not a good start to the day | tomzimerman | |
| 05/4/2024 07:10 | Changed results date, didn’t they know auditors need more time yesterday? Poor | davemac3 | |
| 04/4/2024 09:55 | HSBC ungraded as buy | blackhorse23 | |
| 04/4/2024 09:51 | Looking bullish | blackhorse23 | |
| 03/4/2024 14:13 | Financial summaryThe Group delivered record see-through1 revenues in the Period of £182.7m (FY22: £172.0m), up 6% versus the prior period and up 7% at constant exchange rates ("CER"). Excluding sales from ScarAway and the US rights to Kelo-Cote in Q1 23, both acquired in March 2022 (the "US Acquisition"), like-for-like see-through revenues increased 6% CER. Continued strong consumer demand, particularly in China, drove significant recovery in Kelo-Cote franchise revenues in H2, leading to FY23 revenues of £63.2m, up 29% CER (FY22: £50.0m). Nizoral revenues increased 3% CER to £21.7m (FY22: £21.8m) whilst Amberen revenues declined 6% CER on an underlying basis (excluding the leading discount store account that was lost in 2022) and decreased 25% CER to £11.2m (FY22: £14.9m) on a reported basis. With Other Consumer brands up 5% CER to £40.3m (FY22: £38.4m), total see-through Consumer Healthcare revenues increased 11% CER to £136.4m. Prescription Medicine revenues were stable at £46.3m (FY22: £46.8m), reflecting a strong recovery in H2 as expected, as previously out of stock products became available. Underlying profit for the Period is anticipated to be in-line with market expectations. | blackhorse23 | |
| 03/4/2024 14:01 | You continue to plaster BBs with your pretend sales Blackhorse23 - 03 Apr 2024 - 12:29:37 - 1019 of 1021 Ondo InsurTech - ONDO What is future of this company? Only health care company I have invested in is APH , looking for another one Blackhorse23 - 03 Apr 2024 - 12:28:21 - 57465 of 57466 Avacta – Innovative and Disruptive Technologies for Global Health Markets - AVCT APH [LSE] share price is doing well, excellent profitable healthcare company. Right decision moved from here Blackhorse23 - 03 Apr 2024 - 12:08:11 - 17989 of 17998 SkinBioTherapeutics PLC - Multi $bn skin health opportunities. - SBTX Money moving to APH [LSE] , excellent profitable healthcare company. Blackhorse23 - 03 Apr 2024 - 12:07:45 - 12058 of 12060 Deltex Medical - a British success story! - DEMG Money moving to APH [LSE] , excellent profitable healthcare company Please stop | wad collector |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
